Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration
Rein S, Lodi S, Logan R, Touloumi G, Antoniadou A, Wittkop L, Bonnet F, van Sighem A, van der Valk M, Reiss P, Klein M, Young J, Jarrin I, Monforte A, Tavelli A, Meyer L, Tran L, Gill M, Lang R, Surial B, Haas A, Justice A, Rentsch C, Phillips A, Sabin C, Miro J, Trickey A, Ingle S, Sterne J, Hernán M, Collaboration A. Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration. The Lancet HIV 2023, 10: e723-e732. PMID: 37923486, PMCID: PMC10695103, DOI: 10.1016/s2352-3018(23)00233-3.Peer-Reviewed Original ResearchConceptsART-experienced individualsCardiovascular eventsTarget trialsART regimensRisk ratioTreatment strategiesRisk differenceEligibility criteriaIntegrase strand transfer inhibitor useAntiretroviral Therapy Cohort CollaborationIntegrase strand transfer inhibitorsPooled logistic modelART-naive individualsHIV RNA measurementsHIV-CAUSAL CollaborationNational InstituteStrand transfer inhibitorsLogistic regression modelsART regimenCohort CollaborationAntiretroviral therapyInhibitor useBlood pressureINSTI useClinical dataChallenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data
Hulme W, Williamson E, Horne E, Green A, McDonald H, Walker A, Curtis H, Morton C, MacKenna B, Croker R, Mehrkar A, Bacon S, Evans D, Inglesby P, Davy S, Bhaskaran K, Schultze A, Rentsch C, Tomlinson L, Douglas I, Evans S, Smeeth L, Palmer T, Goldacre B, Hernán M, Sterne J. Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data. Annals Of Internal Medicine 2023, 176: m21-4269. PMID: 37126810, PMCID: PMC10152408, DOI: 10.7326/m21-4269.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccineRandomized trialsObservational studyCOVID-19 vaccinationDuration of protectionBooster vaccinationFirst doseTrial emulationNew virus variantsVaccinated personsEligible personsVaccine rolloutVaccinationTarget trialsVirus variantsTrialsVaccineTime-varying variablesBaselineRobust evidenceSingle trial approachRapid uptakePersonsConfoundersDose